$8356 | SAVE $1,139 | Single User
$16711 | SAVE $2,279 | Site License
$25067 | SAVE $3,418 | Enterprise License

OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024
[Published by Global Data]

Published by Global Data: 09 Oct 2015 | 17750 | In Stock

Introduction

OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024

Summary

Clostridium difficile, a Gram-positive, spore-forming, toxin-producing, non-invasive, anaerobic bacterium, is the causative organism of C. difficile infection (CDI), which is commonly associated with colitis, as well as C. difficile-associated diarrhea (CDAD). CDI onset begins with colonization of the intestinal tract with C. difficile through community-acquired or healthcare-associated means. C. difficile has been identified as a major cause of antibiotic-associated pseudomembranous colitis and diarrhea, with the earliest cases largely attributed to clindamycin. As penicillins and cephalosporins became more widely used throughout the years, their administration also became associated with an increased risk of developing CDAD. Since 2000, CDIs have become more frequent, more severe, more difficult to treat using existing therapies, and more likely to recur than previously described. These realities, along with increasing threat of antibiotic resistance, underscore the importance of developing CDI-specific therapies and bringing them to market.

For the purposes of this report, GlobalData defines the global CDI market to include sales of therapeutic and prophylactic agents aimed at treatment and prevention of CDI and CDAD in patients 18 years and older across the 7MM, which is comprised of the US, 5EU (France, Germany, Italy, Spain, and the UK), and Japan. GlobalData anticipates a major driver of market growth to be the steady increase in uptake of novel CDI-specific antibiotics once they are approved, but the arrival of non-antibiotic products to the market, such as rationally designed microbiologics and vaccines, are poised to make the biggest clinical impact if approved.

Highlights

Key Questions Answered

- Based on interviews with key opinion leaders (KOLs), GlobalData has identified the major unmet needs in the CDI marketplace. Will the leading therapeutic and prophylactic pipeline agents fulfil these unmet needs during the forecast period (2014-2024)?

- What research and development (R&D) strategies will companies leverage to compete in the future CDI marketplace?

- What adjunctive therapies to standard of care (SOC) antibiotics are poised to make a major clinical and commercial impact?

- What clinical and commercial factors are likely to influence CDI product uptake in the US and 5EU (France, Germany, Italy, Spain, and the UK) and Japan (7MM)?

Key Findings

- GlobalData projects CDI therapeutics and prophylactics market in the 7MM to grow from approximately 6m in 2014 to a little over .5bn in 2024, at a compound annual growth rate (CAGR) of 15.8%. This growth will be driven by the increased uptake of novel adjunctive therapies to SOC antibiotics, increased use of Merck’s first-to-market antibiotic Dificid, and the arrival of ACAM-CDIFF, the world’s first prophylactic vaccine developed by Sanofi Pasteur to prevent primary infections.

- KOLs interviewed by GlobalData were split on the ability of a prophylactic vaccine developer to demonstrate statistically significant prevention of primary infections in a pivotal Phase III study, specifically citing difficulties reliably anticipating CDI transmission in the patient population. Expert consensus was that non-antibiotic approaches, specifically rationally designed microbiologic therapies, have the potential to shift the treatment paradigm for intractable recurrent infections, although antibiotics should remain the main treatment options through 2024.

- GlobalData anticipates that firms will continue to invest in CDI-specific antibiotics development throughout the forecast period, but product differentiation will remain a difficult task due to the high clinical cure rates with current cost-effective generic antibacterials and the superior sustained cure rate exhibited with Merck’s Dificid.

Scope

- Overview of CDI, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.

- Topline CDI therapeutics and prophylactics market revenue from 2014-2024. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, and R&D strategies for the CDI market.

- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. An interactive clinical and commercial analyzer tool is available.

- Analysis of the current and future market competition in the global CDI market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global CDI therapeutic and prophylactic markets.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the CDI market in the future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents
for OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024 [Published by Global Data]

  • 1 Table of Contents

    1 Table of Contents 12

    1.1 List of Tables 18

    1.2 List of Figures 21

    2 Introduction 23

    2.1 Catalyst 23

    2.2 Related Reports 24

    2.3 Upcoming Related Reports 25

    3 Disease Overview 26

    3.1 Etiology and Pathophysiology 26

    3.1.1 Etiology 26

    3.1.2 Pathophysiology 29

    3.2 Risk Factors and Symptoms 32

    3.3 Disease Management 34

    3.3.1 Diagnosis 36

    3.3.2 Treatment Guidelines 38

    3.3.3 Clinical Practice 39

    3.3.4 Prevention and Control 42

    3.4 Prognosis and Quality of Life 43

    4 Epidemiology 45

    4.1 Disease Background 45

    4.2 Risk Factors and Comorbidities 46

    4.3 Global Trends 48

    4.3.1 7MM: Diagnosed Incidence Rates 50

    4.3.2 7MM: Diagnosed Incident Cases by Epidemiological Association 51

    4.3.3 7MM: Diagnosed Incident Cases by Recurrence 51

    4.4 Forecast Methodology 52

    4.4.1 Sources Used 54

    4.4.2 Sources Not Used 61

    4.4.3 Forecast Assumptions and Methods 63

    4.5 Epidemiological Forecast of CDI (2014-2024) 69

    4.5.1 Diagnosed Incident Cases of All-CDI 69

    4.5.2 Age-Specific Diagnosed Incident Cases of All-CDI 71

    4.5.3 Sex-Specific Diagnosed Incident Cases of All-CDI 73

    4.5.4 Age-Standardized Diagnosed Incidence Rate of All-CDI 75

    4.5.5 Recurrent CDI Cases 76

    4.5.6 Diagnosed Incident Cases of All-CDI by Epidemiological Association 78

    4.6 Discussion 80

    4.6.1 Epidemiological Forecast Insight 80

    4.6.2 Limitations of the Analysis 82

    4.6.3 Strengths of the Analysis 82

    5 Current Treatment Options 83

    5.1 Overview 83

    5.2 Product Profiles - Recommended Antibiotic Therapies 85

    5.2.1 Metronidazole 85

    5.2.2 Vancomycin 92

    5.2.3 Dificid (fidaxomicin) 97

    5.3 Other Antibiotic Therapies 106

    5.3.1 Targocid (teicoplanin) 106

    5.3.2 Tygacil (tigecycline) 106

    5.3.3 Xifaxan (rifaximin) 107

    5.4 Other Drug Interventions 108

    5.4.1 Immunotherapy 108

    5.5 Non-Drug Interventions 108

    5.5.1 Fecal Microbiota Transplant 109

    5.5.2 Probiotics 112

    5.5.3 Surgical Procedures 113

    6 Unmet Needs Assessment and Opportunity Analysis 116

    6.1 Overview 116

    6.2 Improved Treatment Options for Recurrent CDI 119

    6.2.1 Unmet Need 119

    6.2.2 Gap Analysis 120

    6.2.3 Opportunity 123

    6.3 Prophylactic Products to Prevent CDI 126

    6.3.1 Unmet Need 126

    6.3.2 Gap Analysis 127

    6.3.3 Opportunity 128

    6.4 Standardize, Streamline, and Confirm Long-Term Safety of FMT 129

    6.4.1 Unmet Need 129

    6.4.2 Gap Analysis 130

    6.4.3 Opportunity 131

    6.5 Products to Reduce Morbidity and Mortality in Patients with Severe-Complicated CDI 132

    6.5.1 Unmet Need 132

    6.5.2 Gap Analysis 133

    6.5.3 Opportunity 134

    6.6 Clinically Proven CDI Risk Criteria and Prediction Models 134

    6.6.1 Unmet Need 134

    6.6.2 Gap Analysis 135

    6.6.3 Opportunity 136

    6.7 Improve Surveillance and Prevent Transmission and Outbreaks 137

    6.7.1 Unmet Need 137

    6.7.2 Gap Analysis 138

    6.7.3 Opportunity 139

    7 Research and Development Strategies 140

    7.1 Overview 140

    7.2 Current Approaches to CDI Product Development 142

    7.2.1 Antibiotics 142

    7.2.2 Non-Antibiotic Adjunctive Therapeutics 143

    7.2.3 Non-Antibiotic Prophylactic Agents 148

    7.2.4 Vaccines 149

    7.3 Clinical Trial Design 150

    7.3.1 Therapeutic Agents 150

    7.3.2 Prophylactic Agents 153

    7.4 Special Considerations for Future Clinical Development 155

    7.4.1 Patient Selection in Late-Stage Efficacy Studies for Prophylactic Products 155

    7.4.2 Active Comparators and Superiority Trial Designs for New CDI-Specific Antibiotics 157

    7.4.3 Rationally Designed Microbiologics Need to Show Superior Safety Profiles Compared to FMT 158

    8 Pipeline Assessment 160

    8.1 Overview 160

    8.2 Promising Products in Clinical Development 161

    8.3 Therapeutic Agents - Biologics and Immunotherapies 164

    8.3.1 Actoxumab and Bezlotoxumab (anti-C. difficile toxins A and B) 164

    8.4 Therapeutic Agents - Antibiotics 174

    8.4.1 Cadazolid 174

    8.4.2 Surotomycin 179

    8.4.3 SMT19969 185

    8.5 Therapeutic Agents - Microbiologics 189

    8.5.1 SER-109 (firmacute eubacterial spores, purified suspensions, encapsulated) 189

    8.5.2 RBX2660 (microbiota suspension) 196

    8.6 Prophylactic Agents - Vaccines 202

    8.6.1 ACAM-CDIFF 202

    8.6.2 VLA84 208

    8.6.3 PF-06425090 214

    8.7 Other Innovative Products and Approaches to CDI Prevention and Treatment 220

    8.7.1 LFF571 220

    8.7.2 Ramoplanin 223

    8.7.3 VP20621 (non-toxigenic C. difficile strain M3 spores) 226

    8.7.4 SYN-004 231

    8.8 Other CDI Products in Development 233

    9 Pipeline Valuation Analysis 235

    9.1 Clinical Benchmark of Key Pipeline Products 235

    9.1.1 Therapeutic Agents 235

    9.1.2 Prophylactic Agents 236

    9.2 Commercial Benchmark of Key Pipeline Products 237

    9.2.1 Therapeutic Agents 237

    9.2.2 Prophylactic Agents 239

    9.3 Competitive Assessment 240

    9.3.1 Therapeutic Agents 240

    9.3.2 Prophylactic Agents 242

    9.4 Top-Line 10-Year Forecast 244

    9.4.1 US 250

    9.4.2 5EU 253

    9.4.3 Japan 257

    10 Appendix 261

    10.1 Bibliography 261

    10.2 Abbreviations 295

    10.3 Methodology 299

    10.4 Forecasting Methodology 299

    10.4.1 CDI Patient Population Segmentation 299

    10.4.2 Percent Product-Treated Patients 300

    10.4.3 Products Included in Each Therapeutic Class 302

    10.4.4 Pipeline Product Projected Launch Dates 303

    10.4.5 General Pricing Assumptions 303

    10.4.6 Individual Product Assumptions 304

    10.4.7 Pricing of Pipeline Products 311

    10.5 Primary Research 315

    10.5.1 Physicians and Specialists Included in this Study 315

    10.5.2 Online Survey of High-Prescribing Physicians 317

    10.6 About the Authors 318

    10.6.1 Analyst 318

    10.6.2 Epidemiologist 318

    10.6.3 Therapy Area Director 319

    10.6.4 Global Director of Therapy Analysis and Epidemiology 319

    10.6.5 Global Head of Healthcare 320

    10.7 About GlobalData 321

    10.8 Disclaimer 321

List Of Tables
in OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024 [Published by Global Data]

1.1 List of Tables

Table 1: Antimicrobial Agents that May Induce CDI, CDAD, and Colitis 27

Table 2: Physiological Effects of C. difficile Toxins A and B 31

Table 3: Risk Factors Associated with CDI and CDAD 33

Table 4: Clinical Variants of CDI and Associated Symptoms 34

Table 5: Summary of Stool Laboratory Diagnostic Testing for C. difficile 37

Table 6: CDI Severity Scoring System and Summary of Recommended Treatments 41

Table 7: Risk Factors and Comorbidities for CDI 47

Table 8: Definitions of CDI Segmentations 53

Table 9: 7MM, Sources of CDI Diagnosed Incidence Data 54

Table 10: 7MM, Sources of CDI Recurrence Rates 55

Table 11: 7MM, Sources of CDI Epidemiological Association 56

Table 12: 7MM, Sources Not Used in Epidemiological Analysis of CDI 62

Table 13: 7MM, Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, Selected Years 2014-2024 70

Table 14: 7MM, Age-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014. 72

Table 15: 7MM, Sex-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, N, 2014 74

Table 16: Product Profile - Metronidazole 88

Table 17: Adverse Reactions Reported During Treatment with Metronidazole 89

Table 18: Metronidazole SWOT Analysis, 2015 91

Table 19: Product Profile - Vancomycin 94

Table 20: Clinical Success of Vancomycin-Treated Subjects in Two Clinical Trials 95

Table 21: Common Adverse Reactions for Vancomycin in Treating CDAD* 96

Table 22: Vancomycin SWOT Analysis, 2015 97

Table 23: Product Profile - Dificid 100

Table 24: Dificid Pivotal Phase III Clinical Trials Response Rates 102

Table 25: Dificid Pivotal Phase III Clinical Trials Sustained Clinical Response at 25 Days After Treatment According to C. difficile Strain 103

Table 26: Selected Adverse Reactions with an Incidence of ≥2% Reported in Patients Treated with Dificid in Controlled Trials 104

Table 27: Dificid SWOT Analysis, 2015 105

Table 28: Unmet Need and Opportunity in Clostridium difficile Infections 119

Table 29: Key Products in the CDI Market by Therapeutic Class, 2015 141

Table 30: Clinical Trial Designs for CDI Pipeline Therapeutic Agents 152

Table 31: Clinical Trial Designs for CDI Pipeline Prophylactic Agents 155

Table 32: Promising Products in Clinical Development for CDIs, 2015 163

Table 33: Product Profile - Actoxumab and Bezlotoxumab 167

Table 34: Efficacy of Actoxumab and Bezlotoxumab in Terms of CDI Recurrence, Phase II Trial 170

Table 35: Most Common AEs and SAEs Documented After Treatment with Actoxumab and Bezlotoxumab, Phase II Triala 172

Table 36: Actoxumab and Bezlotoxumab SWOT Analysis, 2015 173

Table 37: Product Profile - Cadazolid 176

Table 38: Efficacy Results from Cadazolid Phase II Trial - Modified Intent-to-Treat Populationa 177

Table 39: Cadazolid SWOT Analysis, 2015 179

Table 40: Product Profile - Surotomycin 181

Table 41: Efficacy Results from Surotomycin Phase II Trial - Modified Intent-to-Treat Populationa 183

Table 42: Surotomycin SWOT Analysis, 2015 184

Table 43: Product Profile - SMT19969 187

Table 44: SMT19969 SWOT Analysis, 2015 189

Table 45: Product Profile - SER-109 192

Table 46: SER-109 SWOT Analysis, 2015 195

Table 47: Product Profile - RBX2660 198

Table 48: RBX2660 SWOT Analysis, 2015 201

Table 49: Product Profile - ACAM-CDIFF 204

Table 50: Formulations and Dosing Schedules for ACAM-CDIFF Phase II Trial 205

Table 51: ACAM-CDIFF SWOT Analysis, 2015 208

Table 52: Product Profile - VLA84 211

Table 53: Doses and Dosing Schedules in VLA84 Phase I Trial* 212

Table 54: VLA84 SWOT Analysis, 2015 214

Table 55: Product Profile - PF-06425090 217

Table 56: PF-06425090 SWOT Analysis, 2015 219

Table 57: Innovative Early-Stage Approaches to CDI Prevention and Treatment, 2015 220

Table 58: Phase II Clinical Trial Efficacy Data for LFF571 222

Table 59: Phase II Clinical Trial Safety Data for LFF571 223

Table 60: Efficacy Data from Phase II Clinical Trial of VP20621 228

Table 61: Safety Data from Phase II Clinical Trial of VP20621 229

Table 62: Other CDI Products in Development, 2015 233

Table 63: Clinical Benchmarking of Key CDI Therapeutic Agents, 2015 236

Table 64: Clinical Benchmarking of Key CDI Pipeline Prophylactic Agents, 2015 237

Table 65: Commercial Benchmarking of Key CDI Therapeutic Agents, 2015 238

Table 66: Commercial Benchmarking of Key CDI Pipeline Prophylactic Agents, 2015 240

Table 67: Top-Line Global Sales Forecasts for CDI Therapeutic and Prophylactic Agents, 2014-2024* 246

Table 68: Key Events Impacting Sales from CDI Therapeutics and Prophylactics, 2014-2024 248

Table 69: Global CDI Products Market - Drivers and Barriers, 2014-2024 249

Table 70: CDI Patient Population Segmentations in the 7MM - Secondary Sources Leveraged 300

Table 71: Patient Populations Targeted by CDI Marketed and Pipeline Product Developers 301

Table 72: CDI Marketed and Pipeline Products Broken Down by Therapeutic Class 302

Table 73: Key Pipeline Product Projected Launch Dates by Region 303

Table 74: High-Prescribing Physicians (Non-KOLs) Surveyed, By Country 317

List Of Figures, Charts and Diagrams
in OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024 [Published by Global Data]

1.2 List of Figures

Figure 1: Examples of C. difficile-Associated Diseases 26

Figure 2: Overview of the Pathogenesis of CDAD 30

Figure 3: Top-Level Overview of International Treatment Algorithm for CDI and CDAD 39

Figure 4: Incidence Rate for CDI in the 7MM, 2014 49

Figure 5: Case Flow Map for the US 57

Figure 6: Case Flow Map for the 5EU and Japan 58

Figure 7: 7MM, Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014-2024 71

Figure 8: Age-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, Both Sexes, N, 2014 73

Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of All-CDI, Ages ≥18 Years, N, 2014 75

Figure 10: 7MM, Age-Standardized Diagnosed Incidence Rates of All-CDI, 2014 76

Figure 11: 5EU and Japan, Recurrent CDI Cases, Ages ≥18 Years, N, 2014 77

Figure 12: US, Diagnosed Incident Cases of CDI Stratified by Recurrence, Ages ≥18 Years, N, 2014 78

Figure 13: 5EU and Japan, Diagnosed Incident Cases of All-CDI Stratified by Epidemiological Association, Ages ≥18 Years, N, 2014 79

Figure 14: US, Diagnosed Incident Cases of All-CDI by Epidemiological Association, Ages ≥18 Years, N, 2014 80

Figure 15: Current Treatment Options for CDIs 85

Figure 16: Competitive Assessment of Key CDI Therapeutic Agents, 2015 242

Figure 17: Competitive Assessment of Key CDI Pipeline Prophylactic Agents, 2015 244

Figure 18: Global Sales from CDI Therapeutic and Prophylactic Agents by Region, 2014 and 2024* 247

Figure 19: US Sales from CDI Therapeutic Agents, 2014 and 2024* 251

Figure 20: US Sales from CDI Prophylactic Agents, 2014-2024 253

Figure 21: 5EU Sales from CDI Therapeutic Agents, 2014 and 2024* 255

Figure 22: 5EU Sales from CDI Prophylactic Agents, 2014-2024 257

Figure 23: Japan Sales from CDI Therapeutic Agents, 2014 and 2024* 258

Figure 24: Japan Sales from CDI Prophylactic Agents, 2014-2024 260

Additional Details

Publisher

Global Data

Publisher Information

Reference

17750 | GDHC037POA

Number of Pages

322

Report Format

PDF

Global Data Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Huntington’s Disease - Opportunity Analysis and Forecast to 2024SummaryHuntingt...
03 May 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Head and Neck Squamous Cell Carcinoma - Opportunity Analysis and Forecast to 20...
02 Feb 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: B-Cell Non-Hodgkin’s Lymphoma (NHL) - Opportunity Analysis and Forecasts to 202...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024S...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024SummaryVasculitis is a fa...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Small Cell Lung Cancer (SCLC) - Opportunity Analysis and Forecasts to 2024Summa...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Pulmonary Arterial Hypertension - Opportunity Analysis and Forecast to 2024Summ...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Hodgkin’s Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Hodgkin’s Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024SummaryHodg...
01 Jan 2016 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024
OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024SummaryGlioblastoma mu...
22 Dec 2015 by Global Data USD $8,356 (normally
USD $9,495)
More Info
SAVE 12% today! OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024
OpportunityAnalyzer: Benign Prostatic Hyperplasia - Opportunity Analysis and Forecast to 2024Summary...
08 Sep 2015 by Global Data USD $8,356 (normally
USD $9,495)
More Info

This report is published by Global Data

Download Free Report Summary PDF

OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024 [Published by Global Data] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...